S
Shigemi Aizawa
Researcher at University of Tokyo
Publications - 10
Citations - 1185
Shigemi Aizawa is an academic researcher from University of Tokyo. The author has contributed to research in topics: Gene & Transmembrane domain. The author has an hindex of 9, co-authored 10 publications receiving 1155 citations. Previous affiliations of Shigemi Aizawa include Tokyo University of Science.
Papers
More filters
Journal ArticleDOI
Identification of TRAF6, a Novel Tumor Necrosis Factor Receptor-associated Factor Protein That Mediates Signaling from an Amino-terminal Domain of the CD40 Cytoplasmic Region
Takaomi Ishida,Seiichi Mizushima,Sakura Azuma,Norihiko Kobayashi,Tadashi Tojo,Kimie Suzuki,Shigemi Aizawa,Toshiki Watanabe,George Mosialos,Elliott Kieff,Tadashi Yamamoto,Jun-ichiro Inoue +11 more
TL;DR: Results suggest that TRAF6 could mediate the CD40 signal that is transduced by the amino-terminal domain (230-245) of theCD40 cytoplasmic region and appears to be independent of other known TRAF family proteins.
Journal ArticleDOI
Tumor Necrosis Factor Receptor-associated Factor (TRAF) 5 and TRAF2 Are Involved in CD30-mediated NFκB Activation
Shigemi Aizawa,Hiroyasu Nakano,Takaomi Ishida,Ryouichi Horie,Masae Nagai,Kinji Ito,Hideo Yagita,Ko Okumura,Jun-ichiro Inoue,Toshiki Watanabe +9 more
TL;DR: TRAF2 and TRAF5 directly interact with CD30 and are involved in NFκB activation by CD30 signaling, indicating an interplay of these TRAF proteins.
Journal ArticleDOI
Dual targeting of transformed and untransformed HTLV-1–infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia
Mariko Watanabe,Takeo Ohsugi,Momoko Shoda,Takaomi Ishida,Shigemi Aizawa,Masae Maruyama-Nagai,Atae Utsunomiya,Shin Koga,Yasuaki Yamada,Shimeru Kamihira,Akihiko Okayama,Hiroshi Kikuchi,Kimiharu Uozumi,Kazunari Yamaguchi,Masaaki Higashihara,Kazuo Umezawa,Toshiki Watanabe,Ryouichi Horie +17 more
TL;DR: It is concluded that NF-kappaB is a potential molecular target for treatment and prevention of ATL and dehydroxymethylepoxyquinomicin is a promising compound allowing the translation of this strategy into clinical medicine.
Journal ArticleDOI
The Clonal Expansion of Human T Lymphotropic Virus Type 1–Infected T Cells: A Comparison between Seroconverters and Long-Term Carriers
Gen-ichi Tanaka,Akihiko Okayama,Toshiki Watanabe,Shigemi Aizawa,Sherri O. Stuver,Sherri O. Stuver,Nancy Mueller,Chung-Cheng Hsieh,Hirohito Tsubouchi +8 more
TL;DR: The clonality of the HTLV-1-infected T cells in the adult seroconverters, who had been newly infected via HTLV -1-carrier spouses, was more heterogeneous and less stable than that of theHTLV- 1- Infected T Cells in long-term carriers, who were more likely to have been infected during infancy.
Journal ArticleDOI
The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-κB activation in anaplastic large cell lymphoma
Ryouichi Horie,Ryouichi Horie,Mariko Watanabe,Takaomi Ishida,Tsukasa Koiwa,Shigemi Aizawa,Kinji Itoh,Masaaki Higashihara,Marshall E. Kadin,Toshiki Watanabe +9 more
TL;DR: It is shown that NPM-ALK impedes CD30 signaling and NF-kappaB activation and can also induce an ALCL phenotype, distinguishing ALCL cells from H-RS cells of T cell origin.